ETNB has been granted a new patent
Mar 12, 2025, 10:39 PM
-40.16%
What does ETNB do
89bio, a San Francisco-based biopharmaceutical company, focuses on therapies for liver and cardio-metabolic diseases, with its lead candidate, pegozafermin, targeting nonalcoholic steatohepatitis and severe hypertriglyceridemia. The company went public on November 11, 2019, and employs 70 people.
ETNB filed a patent for "therapeutic regimens and methods of treatment of nash using mutant fgf-21 peptide conjugates" on Thu, August 24, 2023.
📡️ Health Care
Patents
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.